TY - JOUR
T1 - An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation
AU - Casey, Stephanie C.
AU - Li, Yulin
AU - Felsher, Dean W.
N1 - Funding Information:
Acknowledgments The authors acknowledge current and former members of the Felsher laboratory. Within the Felsher laboratory, research has been funded by the Burroughs Welcome Fund Career Award, the Damon Runyon Foundation Lilly Clinical Investigator Award, NIH RO1 Grant Number CA 089305, 105102, 170378 PQ22, U54CA149145, U54CA143907, National Cancer Institute’s In-vivo Cellular and Molecular Imaging Center Grant Number CA 114747, Integrative Cancer Biology Program Grant Number CA 112973, NIH/ NCI PO1 Grant Number CA034233, and the Leukemia and Lymphoma Society Translational Research Grant Number R6223-07 (D.W.F.). S.C.C. was previously supported by the Stanford University Cellular and Molecular Immunobiology Training Grant (NIH, 5 T32 AI07290) and is currently supported by an NIH NRSA from the NCI (F32CA177139).
PY - 2014/5
Y1 - 2014/5
N2 - Tumors are genetically complex and can have a multitude of mutations. Consequently, it is surprising that the suppression of a single oncogene can result in rapid and sustained tumor regression, illustrating the concept that cancers are often "oncogene addicted." The mechanism of oncogene addiction has been presumed to be largely cell autonomous as a consequence of the restoration of normal physiological programs that induce proliferative arrest, apoptosis, differentiation, and/or cellular senescence. Interestingly, it has recently become apparent that upon oncogene inactivation, the immune response is critical in mediating the phenotypic consequences of oncogene addiction. In particular, CD4+ T cells have been suggested to be essential to the remodeling of the tumor microenvironment, including the shutdown of host angiogenesis and the induction of cellular senescence in the tumor. However, adaptive and innate immune cells are likely involved. Thus, the effectors of the immune system are involved not only in tumor initiation, tumor progression, and immunosurveillance, but also in the mechanism of tumor regression upon targeted oncogene inactivation. Hence, oncogene inactivation may be an effective therapeutic approach because it both reverses the neoplastic state within a cancer cell and reactivates the host immune response that remodels the tumor microenvironment.
AB - Tumors are genetically complex and can have a multitude of mutations. Consequently, it is surprising that the suppression of a single oncogene can result in rapid and sustained tumor regression, illustrating the concept that cancers are often "oncogene addicted." The mechanism of oncogene addiction has been presumed to be largely cell autonomous as a consequence of the restoration of normal physiological programs that induce proliferative arrest, apoptosis, differentiation, and/or cellular senescence. Interestingly, it has recently become apparent that upon oncogene inactivation, the immune response is critical in mediating the phenotypic consequences of oncogene addiction. In particular, CD4+ T cells have been suggested to be essential to the remodeling of the tumor microenvironment, including the shutdown of host angiogenesis and the induction of cellular senescence in the tumor. However, adaptive and innate immune cells are likely involved. Thus, the effectors of the immune system are involved not only in tumor initiation, tumor progression, and immunosurveillance, but also in the mechanism of tumor regression upon targeted oncogene inactivation. Hence, oncogene inactivation may be an effective therapeutic approach because it both reverses the neoplastic state within a cancer cell and reactivates the host immune response that remodels the tumor microenvironment.
KW - MYC
KW - Oncogene addiction
KW - Tumor immunology
KW - Tumor microenvironment
KW - Tumor recurrence
UR - http://www.scopus.com/inward/record.url?scp=84901455062&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84901455062&partnerID=8YFLogxK
U2 - 10.1007/s12026-014-8503-6
DO - 10.1007/s12026-014-8503-6
M3 - Review article
C2 - 24791942
AN - SCOPUS:84901455062
SN - 0257-277X
VL - 58
SP - 282
EP - 291
JO - Immunologic Research
JF - Immunologic Research
IS - 2-3
ER -